SUBSCRIBE
SUBSCRIBE

SELLAS Life Sciences Group

NEWS
Drug Development
Clinical Catch-Up: 3’s the Charm for Pfizer-BioNTech Vaccine in Kids & More
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
May 27, 2022
 · 
10 min read
 · 
Mark Terry
Drug Development
Sellas Reports Promising Data from Combination Trials in Ovarian Cancer and Mesothelioma
Positive results from Sellas Life Sciences Group’s Phase I/II trial using galinpepimut-S (GPS) as a combination therapy with pembrolizumab (Keytruda®) were announced Wednesday, shortly after similarly positive news was issued from a combination study in which GPS was evaluated as a treatment for mesothelioma.
July 1, 2021
 · 
4 min read
 · 
Gail Dutton
JOBS
IN THE PRESS
Press Releases
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 14, 2024
 · 
9 min read
Press Releases
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
November 5, 2024
 · 
5 min read
Press Releases
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
October 15, 2024
 · 
5 min read
News
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 10, 2024
 · 
1 min read
Press Releases
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024
 · 
10 min read
Drug Development
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
August 6, 2024
 · 
4 min read
Press Releases
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
July 31, 2024
 · 
4 min read
FDA
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
July 16, 2024
 · 
5 min read
Drug Development
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
July 8, 2024
 · 
5 min read
Pharm Country
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
June 24, 2024
 · 
4 min read
Load More